Alumni Day: MSc in Applied Cancer Science

Tirapazamine sensitises hypoxic homologous recombination-proficient NSCLC to PARP inhibition.

Jiang Y. et al, (2026), Cell Death Discov

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Huang D. et al, (2026), Cancer Res, 86, 3106 - 3108

CDIN1-Codanin-1 complex defective in congenital dyserythropoietic anaemia type I is an RNA nuclease.

Brolih S. et al, (2026), Nat Commun

Addition of rituximab to first-line treatment of Burkitt lymphoma in children and young adults in Tanzania: a cost-utility analysis

MORRELL L. et al, (2026), Journal of Clinical Oncology Global Oncology

Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.

Jackson A. et al, (2026), Lancet Reg Health Eur, 66

Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.

Murano T. et al, (2026), JCO precision oncology, 10

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Boku S. et al, (2026), JCO precision oncology, 10

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.

Kurniawan A. et al, (2026), Eur J Nucl Med Mol Imaging

CT radiomics for survival risk stratification in resectable colorectal liver metastases: a multi-centre study.

Mian A. et al, (2026), Sci Rep, 16

3D pathology-guided microdissection.

Hsieh H-C. et al, (2026), Nat Methods

A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosis.

Li Q. et al, (2026), iScience, 29

Pragmatism in academic gastrointestinal cancer clinical trials: An analysis of trials conducted by the EORTC gastrointestinal tract cancer group and the unicancer gastrointestinal group.

Puhr HC. et al, (2026), Eur J Cancer, 241

Supplementary Text 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2026)

Supplementary Table 7 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2026)

Supplementary Figure S2 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2026)

Supplementary Table 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2026)

Supplementary Figure S8 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Sakai SA. et al, (2026)

Supplementary Figure 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Hashimoto T. et al, (2026)

Supplementary Figure 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2026)

Supplementary Data 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Woolley CE. et al, (2026)

Search results

Showing results for

Tirapazamine sensitises hypoxic homologous recombination-proficient NSCLC to PARP inhibition.

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

CDIN1-Codanin-1 complex defective in congenital dyserythropoietic anaemia type I is an RNA nuclease.

Addition of rituximab to first-line treatment of Burkitt lymphoma in children and young adults in Tanzania: a cost-utility analysis

Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.

Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.

Identification of a Novel GOLGB1-RET Fusion in Papillary Thyroid Cancer With a Durable Response to Selpercatinib.

Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.

CT radiomics for survival risk stratification in resectable colorectal liver metastases: a multi-centre study.

3D pathology-guided microdissection.

A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosis.

Pragmatism in academic gastrointestinal cancer clinical trials: An analysis of trials conducted by the EORTC gastrointestinal tract cancer group and the unicancer gastrointestinal group.

Supplementary Text 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Supplementary Table 7 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Supplementary Figure S2 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Supplementary Table 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Supplementary Figure S8 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration

Supplementary Figure 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 2 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Supplementary Data 1 from Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis

Study With Us

Cookies on this website

Search results

Showing results for

Study With Us